Immunotherapies have become a pillar of cancer therapies, and ICIs targeting the PD-1/PD-L1 pathway, such as pembrolizumab (Keytruda), nivolumab (Opdivo), and atezolizumab (Tecentriq), have been approved by the FDA to treat different primary tumors presenting with BMs [299]. This evidence concerns the gene CD274 and cancer.